Basilea Pharmaceutica received $13.3 million from BARDA to continue developing ceftibuten-ledaborbactam, an oral antibiotic targeting complicated urinary tract infections caused by multidrug-resistant bacteria. This funding supports preparation for Phase 3 clinical trials, addressing a critical need for effective oral treatments against resistant Gram-negative infections. The total BARDA commitment could reach $133 million, highlighting the strategic importance of this novel beta-lactam/beta-lactamase inhibitor combination. Basilea aims to offer a new solution for infections with limited current oral treatment options.
Pepeto's latest presale stage sold out ahead of schedule, attracting new wallets at twice last month's rate without paid promotion. Built by the original Pepe token team, Pepeto offers a zero-fee exchange with AI contract checks across major blockcha...
Futu Holdings Limited has repurchased approximately US$418 million worth of its American depositary shares (ADSs) as part of its share buyback program initiated in November 2025. The program allows repurchases up to US$800 million and will continue u...
Skills/Compétences Canada officially launched the 2026 Canadian Skills and Technology Olympiad in Toronto, featuring over 500 competitors across 40+ skilled trades and technology contests. The two-day event at Enercare Centre aims to promote skilled ...
The Skills Canada National Competition 2026 officially began in Toronto, featuring over 500 competitors from across Canada competing in more than 40 skilled trade and technology areas. The event aims to inspire youth to pursue careers in trades and t...
Silver prices surged over 140% in 2025, but this sharp rise is now reducing demand, especially in industrial sectors sensitive to economic cycles, according to UBS. Unlike gold, silver lacks strong central bank support, making it more vulnerable to s...
